Parexel International, LLC (“Parexel”) Data Breach Notification Letter — Free Case Review

Parexel International, LLC is a leading global clinical research organization (CRO) that provides comprehensive biopharmaceutical services to help life sciences and biopharmaceutical clients transform scientific discoveries into new medical treatments. Operating at the intersection of healthcare, clinical trials, and advanced pharmaceutical research, Parexel partners with hospitals, research institutions, and global drug developers to manage complex clinical trials across multiple therapeutic areas. Because of its core operations, Parexel routinely collects, processes, and stores vast repositories of highly confidential data, including sensitive participant health information, clinical trial protocols, proprietary research data, and comprehensive personnel records for thousands of clinical researchers, trial participants, and employees worldwide.

In 2025, Parexel International, LLC reported a significant cybersecurity incident to the Texas Attorney General, triggering mandatory data breach notifications. While the precise vectors of such attacks in the clinical research sector often involve sophisticated network intrusions, unauthorized access to centralized clinical trial databases, or third-party vendor compromises, incidents affecting entities of this scale typically expose systemic vulnerabilities in how massive volumes of centralized research and operational data are secured. Given the high-value nature of clinical research data and protected health information, organizations like Parexel are prime targets for malicious threat actors seeking to exfiltrate sensitive files, deploy ransomware, or compromise internal network perimeters.

The data compromised in the Parexel breach typically encompasses a dangerous amalgamation of protected health information, clinical trial data, and personally identifiable information (PII). Exposure of data types such as full names, dates of birth, Social Security numbers, medical record numbers, and clinical trial participation details creates immediate, severe risks for affected individuals. Unlike standard retail data breaches, the compromise of clinical research and health-related records exposes victims to sophisticated medical identity theft, fraudulent insurance billing, and the potential exposure of sensitive medical conditions. Furthermore, the inclusion of core PII leaves victims acutely vulnerable to long-term financial fraud, unauthorized credit openings, and targeted phishing schemes.

As a custodian of sensitive personal and health-related information, Parexel International, LLC was bound by rigorous legal obligations under state and federal frameworks, including state data privacy statutes and applicable provisions of the Health Insurance Portability and Accountability Act (HIPAA) governing the handling of protected health information. These legal standards require organizations to implement robust administrative, physical, and technical safeguards—such as multi-factor authentication, advanced endpoint detection, regular vulnerability assessments, and robust data encryption—to prevent unauthorized access. The occurrence of a reportable data breach strongly suggests potential failures in these critical security protocols, raising serious questions about whether Parexel met its legal duty of care.

If you have received a data breach notification letter from Parexel International, LLC, it serves as a formal legal acknowledgment that your private information was compromised due to inadequate data security. Legally, the receipt of this notice establishes standing to participate in a class action lawsuit aimed at holding the company accountable for its security lapses. Under our firm's representation, class members incur no out-of-pocket costs, as we handle all data breach cases on a strict contingency fee basis—meaning you pay absolutely nothing unless we successfully recover compensation on your behalf.